Epileptogenesis is the gradual process by which a normal brain develops epilepsy. Epilepsy is a chronic condition in which seizures occur. These changes to the brain occasionally cause neurons to fire in a hyper-synchronous manner. This hyper-synchronous firing of neurons is called a seizure.
The causes of epilepsy are broadly classified as being genetic, structural/metabolic, or unknown. Anything that causes epilepsy causes epileptogensis, because epileptogenesis is the process of developing epilepsy. Structural causes of epilepsy include neurodegenerative diseases, traumatic brain injury, stroke, brain tumor, infections of the central nervous system, and status epilepticus (a prolonged seizure or a series of seizures occurring in quick succession).
After a brain injury occurs, there is frequently a "silent" or "latent period" lasting months or years in which seizures do not occur; Canadian neurosurgeon Wilder Penfield called this time between injury and seizure "a silent period of strange ripening". During this latent period, changes occur in the structure and physiology of the brain that result in the development of epilepsy. It is this process in which hyperexcitable neural networks form that is referred to as epileptogenesis, and it is during this latent period that symptoms of epilepsy first occur. If researchers come to better understand epileptogenesis, the latent period may provide a chance for healthcare providers to interfere with the development of epilepsy or reduce its severity.
Changes that occur during epileptogenesis are poorly understood but are thought to include cell death, axonal sprouting, reorganization of neural networks, alterations in the release of neurotransmitters, and neurogenesis. These changes cause neurons to become hyperexcitable and can lead to spontaneous seizures.
In addition to chemical processes, the physical structure of neurons in the brain may be altered. In acquired epilepsy in both humans and animal models, pyramidal neurons are lost, and new synapses are formed.
Hyperexcitability, a characteristic feature of epileptogenesis in which the likelihood that neural networks will be activated is increased, may be due to loss of inhibitory neurons that would normally balance out the excitability of other neurons, such as GABAergic interneurons. Neuronal circuits that are epileptic are known for being hyperexcitable and for lacking the normal balance of glutamatergic neurons (those that usually increase excitation) and GABAergic ones (those that decrease it). In addition, the levels of GABA and the sensitivity of GABAA receptors to the neurotransmitter may decrease, resulting in less inhibition.
Glutamate receptor activation
It is believed that activation of biochemical receptors on the surfaces of neurons is involved in epileptogenesis; these include the TrkB neurotrophin receptor and both ionotropic glutamate receptors and metabotropic glutamate receptors (those that are directly linked to an ion channel and those that are not, respectively). Each of these types of receptor may, when activated, cause an increase in the concentration of calcium ions (Ca2+) within the area of the cell on which the receptors are located, and this Ca2+ can activate enzymes such as Src and Fyn that may lead to epileptogenesis.
Excessive release of the neurotransmitter glutamate is widely recognized as an important part of epileptogenesis early after a brain injury, including in humans. Excessive release of glutamate results in excitotoxicity, in which neurons are excessively depolarized, intracellular Ca2+ concentrations increase sharply, and cellular damage or death results. Excessive glutamatergic activity is also a feature of neuronal circuits after epilepsy has developed, but glutamate does not appear to play an important role in epileptogenesis during the latent period. Another factor in hyperexcitability may include a decrease in the concentration of Ca2+ outside cells (i.e. in the extracellular space) and a decrease in the activity of ATPase in glial cells.
Blood that spills into brain tissue (as may occur in traumatic brain injury or stroke) may play a role in the damage that results in epilepsy, perhaps by depositing hemosiderin or iron into the tissue. Iron from hemoglobin, a molecule in red blood cells, can lead to the formation of free radicals that damage cell membranes; this process has been linked to epileptogenesis.
Epileptogenesis that occurs in human brains has been modeled in a variety of animal models and cell culture models. Epileptogenesis is poorly understood, and increasing understanding of the process may aid researchers in preventing seizures, diagnosing epilepsy, and developing treatments to prevent it.
A major goal of epilepsy research is the identification of therapies to interrupt or reverse epileptogenesis. Studies largely in animal models have suggested a wide variety of possible antiepileptogenic strategies although, to date, no such therapy has been demonstrated to be antiepileptogenic in clinical trials. Some anticonvulsant drugs, including levetiracetam and ethosuximide have shown promising activity in animal models. Other promising strategies are inhibition of interleukin 1β signaling by drugs such as VX-765; modulation of sphingosine 1-phosphate signaling by drugs such as fingolimod; activation of the mammalian target of rapamycin (mTOR) by drugs such as rapamycin; the hormone erythropoietin; and, paradoxically, drugs such as the α2 adrenergic receptor antagonist atipamezole and the CB1 cannabinoid antagonist SR141716A (rimonabant) with proexcitatory activity.
Throughout most of history for which written records exist on the subject, it was probably generally believed that epilepsy came about through a supernatural process. Even within the medical profession, it was not until the 18th century that ideas of epileptogenesis as a supernatural phenomenon were abandoned. However, biological explanations have also long existed, and sometimes explanations contained both biological and supernatural elements.
- McNamara JO, Huang YZ, Leonard AS (October 2006). "Molecular signaling mechanisms underlying epileptogenesis". Sci. STKE. 2006 (356): re12. doi:10.1126/stke.3562006re12. PMID 17033045.
- Armijo JA, Valdizán EM, De Las Cuevas I, Cuadrado A (2002). "Advances in the physiopathology of epileptogenesis: Molecular aspects". Rev Neurol (in Spanish). 34 (5): 409–29. PMID 12040510.
- Noebels, Jeffrey L.; Avoli, Massimo (2012-06-29). Jasper's Basic Mechanisms of the Epilepsies. Oxford University Press. p. 3. ISBN 9780199746545. Retrieved 2014-10-16.
- Herman ST (January 2006). "Clinical trials for prevention of epileptogenesis". Epilepsy Res. 68 (1): 35–8. doi:10.1016/j.eplepsyres.2005.09.015. PMID 16377141.
- Aroniadou-Anderjaska V, Fritsch B, Qashu F, Braga MF (February 2008). "Pathology and pathophysiology of the amygdala in epileptogenesis and epilepsy". Epilepsy Res. 78 (2-3): 102–16. doi:10.1016/j.eplepsyres.2007.11.011. PMC 2272535. PMID 18226499.
- "Post-traumatic epilepsy". Br Med J. 2 (6132): 229. 1978. doi:10.1136/bmj.2.6132.229. PMC 1606365. PMID 98198.
- Firlik KS, Spencer DD (2004). "Surgery of post-traumatic epilepsy". In Dodson WE, Avanzini G, Shorvon SD, Fish DR, Perucca E. The Treatment of Epilepsy. Oxford: Blackwell Science. p. 775. ISBN 0-632-06046-8. Retrieved 2008-06-09.
- Beghi E (2004). "Aetiology of epilepsy". In Dodson WE, Avanzini G, Shorvon SD, Fish DR, Perucca E. The Treatment of Epilepsy. Oxford: Blackwell Science. p. 61. ISBN 0-632-06046-8. Retrieved 2008-06-09.
- Leśkiewicz M, Lasoń W (2007). "The neurochemical mechanisms of temporal lobe epilepsy: an update". Prz. Lek. (in Polish). 64 (11): 960–4. PMID 18409413.
- Kaminski, R. M.; Rogawski, M. A.; Klitgaard, H (2014). "The potential of antiseizure drugs and agents that act on novel molecular targets as antiepileptogenic treatments". Neurotherapeutics. 11 (2): 385–400. doi:10.1007/s13311-014-0266-1. PMC 3996125. PMID 24671870.
- Eadie MJ, Bladin PF (2001). "The interpretation of the epileptic process". A Disease Once Sacred: A History of the Medical Understanding of Epilepsy. London: John Libbey. p. 80. ISBN 0-86196-607-4. Retrieved 2008-06-12.